China Health Group Limited
中國衛生集團有限公司

(Carrying on business in Hong Kong as CHG HS Limited)
(Incorporated in Bermuda with limited liability)
(Stock Code: 673)

DELAY IN DESPATCH OF CIRCULAR IN RELATION TO (I) SUBSCRIPTIONS OF NEW SHARES UNDER SPECIFIC MANDATE; (II) PROPOSED RIGHTS ISSUE ON THE BASIS OF THREE (3) RIGHTS SHARES FOR EVERY TEN (10) SHARES HELD ON THE RECORD DATE; (III) CONNECTED TRANSACTION AND SPECIAL DEAL IN RELATION TO THE UNDERWRITING AGREEMENT; (IV) SPECIAL DEAL IN RELATION TO THE PLACING AGENT AGREEMENT; AND (V) APPLICATION FOR WHITEWASH WAIVER

Financial Adviser to the Company

Optima Capital Limited

Independent Financial Adviser to the Company

紅日資本有限公司
RED SUN CAPITAL LIMITED

Reference is made to the announcement of China Health Group Limited (the "**Company**") dated 22 May 2025 (the "**Announcement**") in relation to, among other things, the Proposal. Capitalised terms used herein shall have the same meanings as those defined in the Announcement unless the context otherwise requires.

As set out in the Announcement, the Circular containing, among others, (i) details of the Subscription Agreements, the Rights Issue, the Underwriting Agreement, the Placing Agent Agreement and the Whitewash Waiver; (ii) a letter of recommendation from the Independent Board Committee in respect of the Subscription Agreements, the Underwriting Agreement, the Placing Agent Agreement and the Whitewash Waiver; (iii) a letter of advice from the Independent Financial Adviser to the Independent Board Committee and the Independent Shareholders in regards of the above; (iv) other information required under the Listing Rules and the Takeovers Code; and (v) a notice convening the SGM, should be despatched to the Shareholders within 15 Business Days from the date of the Announcement pursuant to the Listing Rules and 21 days from the date of the Announcement pursuant to the Takeovers Code (i.e. 12 June 2025).

The consolidated financial results of the Group for the year ended 31 March 2025 (the "**2025 Annual Results**") are being finalised by the Company and planned to be approved by the Board for publication on 30 June 2025. In order to enable the Independent Shareholders to make a properly informed decision on the Proposal with updated financial information, the 2025 Annual Results will be included in the Circular.

Coupled with additional time required to prepare and finalise certain information to be contained in the Circular including, among other things, certain financial information of the Group and the letter of advice from the Independent Financial Adviser, an application has been made to the Executive pursuant to Rule 8.2 of the Takeovers Code for its consent to extend the deadline for the despatch of the Circular to a date falling on or before 11 July 2025, and the Executive has indicated that it is minded to grant its consent for such extension.

By order of the Board
China Health Group Limited
Chung Ho
Chief Executive Officer and Executive Director

Hong Kong, 12 June 2025

As of the date of this announcement, the Board comprises three executive Directors, namely, Mr. Zhang Fan (Chairman), Mr. Chung Ho and Mr. Xing Yong; two non-executive Directors, namely, Mr. Huang Lianhai and Mr. Wang Jingming; and four independent non-executive Directors, namely, Mr. Jiang Xuejun, Mr. Du Yanhua, Mr. Lai Liangquan and Ms. Yang Huimin.

The Directors jointly and severally accept full responsibility for the accuracy of the information contained in this announcement and confirm, having made all reasonable enquiries, that to the best of their knowledge, opinions expressed in this announcement have been arrived at after due and careful consideration and there are no other facts not contained in this announcement, the omission of which would make any statement in this announcement misleading.